Survodutide.
About Survodutide
Survodutide is among the compounds studied in metabolic and weight-regulation research. Dual activation of the glucagon and GLP-1 receptors: combines GLP-1-mediated appetite reduction with glucagon-mediated increases in energy expenditure and hepatic fat oxidation.
Research Application
Phase 2 data (dose-dependent, up to roughly 19% weight loss) and Phase 3 interim results position survodutide as a candidate for obesity and, via the LIVERAGE trials, for liver fibrosis in MASH.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
A growing number of preclinical and clinical studies exist for metabolic peptides, though the volume varies significantly by substance.
- le Roux CW, et al. Lancet Diabetes Endocrinol. 2024;12(3):162–173. PMID 38330987
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Similar Peptides
Question about Survodutide?
We reply personally – via email or Telegram.